Clinical trialNo phase (not a drug trial)Terminated
Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy
- Outcome
- Stopped earlypoor case accural (Other)
- Phase
- No phase (not a drug trial)
- Status
- Terminated
- Study type
- Interventional
- Start
- 22 July 2013
- Ended
- 23 September 2020
- Enrollment
- 11 participants
- Sites
- 1
- Primary outcomes
- Radiological assessment
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 21 October 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The objectives of this study are to study the safety and effect of IRE as a treatment for inoperable hepatic and pancreatic malignancy.
Detailed description public domain (ClinicalTrials.gov)
Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. The use of thermal ablation for tumors adjacent to major blood vessels is not advisable because the "heat-sink effect" owing to blood vessels render the thermal treatment not effective. On the other hand, application of thermal ablation to a tumor adjacent to blood vessels or bile ducts will cause thermal damage to these structures. It has been shown in animal experiments that IRE is effective in causing cell death while blood vessels, bile ducts, and nerves in the vicinity are preserved. Early evidence of clinical studies has shown that IRE is a reasonably safe and effective treatment for pancreatic and hepatic tumors.